Business
USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome
STATEN ISLAND, N.Y., July 17, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical
About this update from Acurx Pharmaceuticals, Inc.
[{"type":"text","content":"STATEN ISLAND, N.Y., July 17, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (\"Acurx\" or the \"Company\"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that a new patent has been granted by the United States Patent and Trademark Office (USPTO) on July 16, 2024. This patent relates to ibezapolstat and its use to treat C. difficile Infection (CDI) while reducing the recurrence of the infection, as well as improving the health of the gut microbiome. This is the latest in the series of granted patents and pending patent applications that Acrux has filed to protect its proprietary technologies in the field of antimicrobials.\n\nRobert J. DeLuccia, Executive Chairman of Acurx, stated: \"This patent is very important and timely as ibezapolstat continues to demonstrate previously unexpected and favorable effects on the gut microbiome while at the same time curing the C. difficile bacterial infection and preventing recurrent infection.\" He further added: \"As we continue to prepare for initiation of our Phase 3 clinical program, we expect this feature of ibezapolstat's selective mechanism of action to be further demonstrated and to be an important competitive advantage over currently available antibiotics by reducing the recurrence of the infection. This could have a dramatically favorable effect on patient outcomes and on reducing downstream healthcare costs.\" \nDavid P. Luci, President & CEO of Acurx stated: \"This latest patent is part of our company's pivotal product, ibezapolstat, which is a two-dimensional antibiotic to cure infections clinically comparable to marketed antibiotics while restoring the microbiome and preventing reinfections which is unusually positive for CDI antibiotics.\"\nAcurx has previously announced that it had a successful FDA End-of- Phase 2 Meeting and Phase 3 Readiness for ibezapolstat for the Treatment of C. difficile Infection. Agreement with FDA was reached on key elements to move forward with its international Phase 3 clinical trial program. Agreement was also reached with FDA on the complete non-clinical and clinical development plan for filing of a New Drug Application (NDA) for marketing approval. Planning continues to advance ibezapolstat into international Phase 3 clinica...